Research hero image
Research
  1. Home
  2. Research
  3. Clinical Trials

Clinical Trials

Vitreoretinal Consultants of NY is nationally recognized for research and clinical trials related to age-related macular degeneration, diabetic eye complications, and more. Not only do clinical trials play a pivotal role in the development of new and improved treatment modalities, but they also provide eligible patients with access to zero-cost retinal care. Below is a list of active trials that are currently available for enrollment, as well as a list of previous trials. For more information on our clinical trials and how to enroll, contact us today.

For more information or to inquire about clinical trials at VRC, please contact Kristen D'Amore at kdamore@vrcny.com or call 516-466-0390 ext. 222.

  • EyePoint Pharmaceuticals, Inc. Pavia Study. A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor( TKI), compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Rethinopaty (NPDR)

  • Retina Consultants of Texas. Magic Study. Faricimab for Retinal Non-Perfusion associated with non-proleferative diabetic retinopathy: The Magic Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial

  • Regeneron Pharmaceuticals. Photon Study. A Randomized, Double- Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema.
  • Rezolute, Inc., A Randomized, Double-Masked, Placebo- Controlled, Parallel-Arm Study to Compare the Efficacy and Safety of RZ-402 in Subjects with Diabetic Macular Edema (DME)
  • Oculis Operations. Diamond 2 Study. A Phase 3 Double-masked, Randomized, Mulicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema- CURRENTLY ENROLLING
  • Alexion Pharm. Onward Study A Phase 2, Double-Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
  • Apellis Pharm. Gale A Phase 3, Open-Label, Multicenter Extension Study to Evaluate The Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
  • Cognition Therapeutics Inc. Magnify Study. A randomized, Double- Blind, Placebo- Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration – CURRENTLY ENROLLING
  • Janssen. Parasol Study. A phase 2b, Randomized, Double- masked, Multicenter, Dose- raging, Sham-Controlled Clinical Trail to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Advanced Age-Related Macular Degeneration- CURRENTLY ENROLLING
  • Apellis Pharm. Garland Study. A Prospective, Multicenter, Open-Label, Observ Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pagcetacoplan ( Syfovre) in Patients with Geographic Atrophy Secondary to Age- Related Macular Degeneration. CURRENTLY ENROLLING
  • Aviceda Therapeutics, Inc. Siglec Study. A Single and Multi Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration. CURRENTLY ENROLLING
  • Belite Bio. Phoenix Study. Phase 3, Multicenter, Randomized, Double-masked, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in the Treatment of Geographic Atrophy- CURRENTLY ENROLLING
  • Bayer. Pulsar Study. Phase 3 Randomized, Double-Masked, Active- Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
  • Genentech, Inc. Portal Study. A multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.
  • Genentech, Inc. Avonelle-X Study. A multicenter, Open- Label Extension Study to Evaluate the Long- Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration.
  • Opthea. Coast Study. A phase 3, Multicentre, Double- Masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in ParticipanNeovascular Age-Related Macular Degenerationts with Neovascular Age related Macular Degeneration
  • Opthea. Shore Study. A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration – CURRENTLY ENROLLING
  • Outlook Therapeutics. Norse Eight Study. Safety and Effectiveness of ONS-5010 Compared to Lucentis in Subjects with Neovascular Age-related Macular Degeneration – UPCOMING
  • F. Hoffmann- La Roche Ltd. Burgundy Study. A Three-part, Phase 1 Study to investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients with Neovascular Age-Related Macular Degeneration – UPCOMING
  • Bayer Quasar Study. Randomized, Double-masked, Active- Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8mg in Macular Edema due to Retinal Vein Occlusion (RVO)
  • Alkeus Pharm. Tease Study. A Phase 2 Multicenter, Randomized, Open Label Study to Investigate the Long-Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease – CURRENTLY ENROLLING